Delving into the Latest Updates on Donor Derived HIV-Specific T-cells (DD HST-NEETs)(Children's National Research Institute) with Synapse

Overview

Basic Info

Drug Type

T-lymphocyte cell therapy

Synonyms-

Target-

Mechanism

Cell replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [5]

Active Indication-

Inactive Indication

Originator Organization

Children's National Research Institute

Active Organization-

Inactive Organization

Children's Research Institute, Inc.

National Cancer Institute

National Heart, Lung & Blood Institute

+ [1]

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

This is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT).

Start Date01 May 2020

Sponsor / Collaborator-

NCT03485963 / Active, not recruitingPhase 1IIT

A Phase I Study to Evaluate the Safety, Immunologic, and Virologic RESponses of HIV-Specific T-cells With Non-escaped Epitope Targeting (HST-NEETs) as a Therapeutic Strategy in HIV-Infected Individuals on Antiretroviral Therapy During Acute And Chronic Infection

This is a phase I, multi-site, study of the safety, immunologic and virologic responses of ex vivo expanded HIV-1 multi-antigen specific T-cell therapy (HST-NEET) as a therapeutic strategy in HIV-infected individuals suppressed on antiretroviral therapy (ART).

Start Date21 Mar 2019

Sponsor / Collaborator-

100 Clinical Results associated with Donor Derived HIV-Specific T-cells (DD HST-NEETs)(Children's National Research Institute)

Login to view more data

100 Translational Medicine associated with Donor Derived HIV-Specific T-cells (DD HST-NEETs)(Children's National Research Institute)

Login to view more data

100 Patents (Medical) associated with Donor Derived HIV-Specific T-cells (DD HST-NEETs)(Children's National Research Institute)

Login to view more data

100 Deals associated with Donor Derived HIV-Specific T-cells (DD HST-NEETs)(Children's National Research Institute)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
AIDS-Related Lymphoma	Phase 2	US	National Heart, Lung & Blood Institute	25 Oct 2021
AIDS-Related Lymphoma	Phase 2	US	National Cancer Institute	25 Oct 2021
AIDS-Related Lymphoma	Phase 2	US	Children's National Research Institute	25 Oct 2021
Darier Disease	Phase 1	US	Children's Research Institute, Inc.	01 May 2020
HIV Infections	Phase 1	US	Children's Research Institute, Inc.	01 May 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03485963 (RESIST, ASH2022) Manual	Phase 1	HIV Infections	6	HST-NEETs	jsbvpqmteq(sqhhmktlpw) = HST-NEETs are safe, can elicit expansion and persistence of HIV-specific T cell populations post-infusion even without prescribed lymphodepletion, and may be associated with durable decreases in the HIV reservoir fmzxbzvazg (qtvvvmwmvg )	Positive	15 Nov 2022